Once-weekly epoetin alfa for treating the anemia of chronic kidney disease

R. Provenzano, L. Gracia-Mayol, P. Suchinda, B. Von Hartitzsch, S. B. Woollen, R. Zabaneh, J. C. Fink, N. R. Boorgu, G. A. Habach, W. McGuffin, M. J. Shaver, D. Chan, A. Trivedi, J. Ahdoot, M. Blumenkrantz, H. L. Al-Mufti, C. Covey, A. Dauer, N. DiDomenico, J. G. Elder & 79 others G. Z. Fadda, E. Feinstein, R. J. Fernandez, J. Glick, J. Golden, M. D. Healy, K. S. Kleinman, P. H. Lee, A. R. Maciejewski, L. Mehandru, J. L. Naughton, R. Oliver, T. Nguyen, R. V. Patek, A. Rahban, D. Ricker, D. Roh, R. Sankaram, L. Schoenfeld, A. Semerjian, M. Shapiro, C. H. Sun, S. Sunderrajan, R. P. Waldman, M. H. Klein, K. C. Kuruvila, H. Lifland, F. Walsh, V. Habwe, Kapil Dev Sethi, M. S. Zonozi, R. K. Kasama, J. Barrero, D. Butcher, V. Bommineni, D. Celaya, J. Cohen, J. DiMare, O. G. Galvez, L. Garcia-Mayol, R. Geronemus, C. M. Glasser, D. S. Hoffman, P. Kar, J. M. Littlefield, J. Mahmood, J. G. Moros, J. Narayan, J. Navarro, E. L. Pellegrini, E. Perez, P. Reddy, A. Sallman, M. Sobel, C. P. Spies, B. Erb, B. T. Fariyike, L. S. Feinsmith, J. Hertel, M. W. Hicks, M. M. Kassem, M. Katz, G. Knowlton, R. Loutoby, C. Martinez, S. T. Murphy, M. J.C. Orig, J. L. Pimentel, P. Pintavorn, R. Shay, A. Vainer, M. J. Wilkowski, D. Williamson, S. B. Woollen, S. DaHal, S. Hallberg, V. Kantamneni, M. Matson, D. Batlle

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Background and aim: Anemia occurs in approximately 47% of patients with chronic kidney disease (CKD) not on dialysis. Recombinant human erythropoietin (r-HuEPO, epoetin alfa) has been proven safe and effective for anemia treatment in patients with CKD using a three times-weekly regimen. The current study was conducted to evaluate the clinical safety and efficacy of a less frequent dosing regimen (once weekly) in this population. Methods: This prospective, multicenter, open-label, non-randomized study enrolled 1,557 adult anemic (hemoglobin (Hb) ≤10 g/dl) CKD patients not on dialysis. Epoetin alfa 10,000 U was administered subcutaneously once weekly for 16 weeks. Titration to 20,000 U once weekly at week 5 was permitted if patients had an increase in Hb < 1 g/dl. Safety and efficacy were assessed by changes in health-related quality of life (Linear Analog Scale Assessment (LASA) and Kidney Disease Questionnaire (KDQ)), changes in hematologic parameters and transfusion utilization, and incidence and severity of adverse events. Results: 1,338 patients were evaluable for efficacy. Mean Hb level increased from 9.1 g/dl at baseline to 11. 6 g/dl at study completion (last observed value after baseline) (p < 0.0001). Overall, 89.8% of patients responded to once-weekly dosing, exhibiting an increase in Hb level of ≥ 1 g/dl from baseline. The percentage of patients that required transfusion decreased from 11.1% (baseline) to 3.7% (during the study) (p < 0.0001). All quality-of-life parameters improved significantly from baseline (p < 0.0001). Mean LASA scores for energy, activity and overall quality of life increased from baseline to study completion by 27.9 mm (70.5%), 24.5 mm (57.0%) and 22.6 mm (47.4%), respectively. All 5 KDQ domains showed statistically significant improvements (p < 0.0001). Hb change was a strong predictor for all 5 KDQ domains and the overall score (p < 0.0001). Treatment with once-weekly epoetin alfa was well tolerated, similar to that reported with three times-weekly dosing. Conclusion: Once-weekly epoetin alfa therapy is safe and effective for treating anemia in patients with CKD not on dialysis, and is associated with significant improvements in functional status and quality of life.

Original languageEnglish (US)
Pages (from-to)392-405
Number of pages14
JournalClinical Nephrology
Volume61
Issue number6
DOIs
StatePublished - Jan 1 2004

Fingerprint

Epoetin Alfa
Chronic Renal Insufficiency
Anemia
Hemoglobins
Kidney Diseases
Quality of Life
Dialysis
Safety
Erythropoietin

Keywords

  • Anemia
  • Chronic kidney disease
  • Epoetin alfa
  • Hemoglobin
  • Once weekly dosing
  • Quality of life

ASJC Scopus subject areas

  • Nephrology

Cite this

Provenzano, R., Gracia-Mayol, L., Suchinda, P., Von Hartitzsch, B., Woollen, S. B., Zabaneh, R., ... Batlle, D. (2004). Once-weekly epoetin alfa for treating the anemia of chronic kidney disease. Clinical Nephrology, 61(6), 392-405. https://doi.org/10.5414/CNP61392

Once-weekly epoetin alfa for treating the anemia of chronic kidney disease. / Provenzano, R.; Gracia-Mayol, L.; Suchinda, P.; Von Hartitzsch, B.; Woollen, S. B.; Zabaneh, R.; Fink, J. C.; Boorgu, N. R.; Habach, G. A.; McGuffin, W.; Shaver, M. J.; Chan, D.; Trivedi, A.; Ahdoot, J.; Blumenkrantz, M.; Al-Mufti, H. L.; Covey, C.; Dauer, A.; DiDomenico, N.; Elder, J. G.; Fadda, G. Z.; Feinstein, E.; Fernandez, R. J.; Glick, J.; Golden, J.; Healy, M. D.; Kleinman, K. S.; Lee, P. H.; Maciejewski, A. R.; Mehandru, L.; Naughton, J. L.; Oliver, R.; Nguyen, T.; Patek, R. V.; Rahban, A.; Ricker, D.; Roh, D.; Sankaram, R.; Schoenfeld, L.; Semerjian, A.; Shapiro, M.; Sun, C. H.; Sunderrajan, S.; Waldman, R. P.; Klein, M. H.; Kuruvila, K. C.; Lifland, H.; Walsh, F.; Habwe, V.; Sethi, Kapil Dev; Zonozi, M. S.; Kasama, R. K.; Barrero, J.; Butcher, D.; Bommineni, V.; Celaya, D.; Cohen, J.; DiMare, J.; Galvez, O. G.; Garcia-Mayol, L.; Geronemus, R.; Glasser, C. M.; Hoffman, D. S.; Kar, P.; Littlefield, J. M.; Mahmood, J.; Moros, J. G.; Narayan, J.; Navarro, J.; Pellegrini, E. L.; Perez, E.; Reddy, P.; Sallman, A.; Sobel, M.; Spies, C. P.; Erb, B.; Fariyike, B. T.; Feinsmith, L. S.; Hertel, J.; Hicks, M. W.; Kassem, M. M.; Katz, M.; Knowlton, G.; Loutoby, R.; Martinez, C.; Murphy, S. T.; Orig, M. J.C.; Pimentel, J. L.; Pintavorn, P.; Shay, R.; Vainer, A.; Wilkowski, M. J.; Williamson, D.; Woollen, S. B.; DaHal, S.; Hallberg, S.; Kantamneni, V.; Matson, M.; Batlle, D.

In: Clinical Nephrology, Vol. 61, No. 6, 01.01.2004, p. 392-405.

Research output: Contribution to journalArticle

Provenzano, R, Gracia-Mayol, L, Suchinda, P, Von Hartitzsch, B, Woollen, SB, Zabaneh, R, Fink, JC, Boorgu, NR, Habach, GA, McGuffin, W, Shaver, MJ, Chan, D, Trivedi, A, Ahdoot, J, Blumenkrantz, M, Al-Mufti, HL, Covey, C, Dauer, A, DiDomenico, N, Elder, JG, Fadda, GZ, Feinstein, E, Fernandez, RJ, Glick, J, Golden, J, Healy, MD, Kleinman, KS, Lee, PH, Maciejewski, AR, Mehandru, L, Naughton, JL, Oliver, R, Nguyen, T, Patek, RV, Rahban, A, Ricker, D, Roh, D, Sankaram, R, Schoenfeld, L, Semerjian, A, Shapiro, M, Sun, CH, Sunderrajan, S, Waldman, RP, Klein, MH, Kuruvila, KC, Lifland, H, Walsh, F, Habwe, V, Sethi, KD, Zonozi, MS, Kasama, RK, Barrero, J, Butcher, D, Bommineni, V, Celaya, D, Cohen, J, DiMare, J, Galvez, OG, Garcia-Mayol, L, Geronemus, R, Glasser, CM, Hoffman, DS, Kar, P, Littlefield, JM, Mahmood, J, Moros, JG, Narayan, J, Navarro, J, Pellegrini, EL, Perez, E, Reddy, P, Sallman, A, Sobel, M, Spies, CP, Erb, B, Fariyike, BT, Feinsmith, LS, Hertel, J, Hicks, MW, Kassem, MM, Katz, M, Knowlton, G, Loutoby, R, Martinez, C, Murphy, ST, Orig, MJC, Pimentel, JL, Pintavorn, P, Shay, R, Vainer, A, Wilkowski, MJ, Williamson, D, Woollen, SB, DaHal, S, Hallberg, S, Kantamneni, V, Matson, M & Batlle, D 2004, 'Once-weekly epoetin alfa for treating the anemia of chronic kidney disease', Clinical Nephrology, vol. 61, no. 6, pp. 392-405. https://doi.org/10.5414/CNP61392
Provenzano R, Gracia-Mayol L, Suchinda P, Von Hartitzsch B, Woollen SB, Zabaneh R et al. Once-weekly epoetin alfa for treating the anemia of chronic kidney disease. Clinical Nephrology. 2004 Jan 1;61(6):392-405. https://doi.org/10.5414/CNP61392
Provenzano, R. ; Gracia-Mayol, L. ; Suchinda, P. ; Von Hartitzsch, B. ; Woollen, S. B. ; Zabaneh, R. ; Fink, J. C. ; Boorgu, N. R. ; Habach, G. A. ; McGuffin, W. ; Shaver, M. J. ; Chan, D. ; Trivedi, A. ; Ahdoot, J. ; Blumenkrantz, M. ; Al-Mufti, H. L. ; Covey, C. ; Dauer, A. ; DiDomenico, N. ; Elder, J. G. ; Fadda, G. Z. ; Feinstein, E. ; Fernandez, R. J. ; Glick, J. ; Golden, J. ; Healy, M. D. ; Kleinman, K. S. ; Lee, P. H. ; Maciejewski, A. R. ; Mehandru, L. ; Naughton, J. L. ; Oliver, R. ; Nguyen, T. ; Patek, R. V. ; Rahban, A. ; Ricker, D. ; Roh, D. ; Sankaram, R. ; Schoenfeld, L. ; Semerjian, A. ; Shapiro, M. ; Sun, C. H. ; Sunderrajan, S. ; Waldman, R. P. ; Klein, M. H. ; Kuruvila, K. C. ; Lifland, H. ; Walsh, F. ; Habwe, V. ; Sethi, Kapil Dev ; Zonozi, M. S. ; Kasama, R. K. ; Barrero, J. ; Butcher, D. ; Bommineni, V. ; Celaya, D. ; Cohen, J. ; DiMare, J. ; Galvez, O. G. ; Garcia-Mayol, L. ; Geronemus, R. ; Glasser, C. M. ; Hoffman, D. S. ; Kar, P. ; Littlefield, J. M. ; Mahmood, J. ; Moros, J. G. ; Narayan, J. ; Navarro, J. ; Pellegrini, E. L. ; Perez, E. ; Reddy, P. ; Sallman, A. ; Sobel, M. ; Spies, C. P. ; Erb, B. ; Fariyike, B. T. ; Feinsmith, L. S. ; Hertel, J. ; Hicks, M. W. ; Kassem, M. M. ; Katz, M. ; Knowlton, G. ; Loutoby, R. ; Martinez, C. ; Murphy, S. T. ; Orig, M. J.C. ; Pimentel, J. L. ; Pintavorn, P. ; Shay, R. ; Vainer, A. ; Wilkowski, M. J. ; Williamson, D. ; Woollen, S. B. ; DaHal, S. ; Hallberg, S. ; Kantamneni, V. ; Matson, M. ; Batlle, D. / Once-weekly epoetin alfa for treating the anemia of chronic kidney disease. In: Clinical Nephrology. 2004 ; Vol. 61, No. 6. pp. 392-405.
@article{409bf812e9104f8e9f14cff9e7ae31cc,
title = "Once-weekly epoetin alfa for treating the anemia of chronic kidney disease",
abstract = "Background and aim: Anemia occurs in approximately 47{\%} of patients with chronic kidney disease (CKD) not on dialysis. Recombinant human erythropoietin (r-HuEPO, epoetin alfa) has been proven safe and effective for anemia treatment in patients with CKD using a three times-weekly regimen. The current study was conducted to evaluate the clinical safety and efficacy of a less frequent dosing regimen (once weekly) in this population. Methods: This prospective, multicenter, open-label, non-randomized study enrolled 1,557 adult anemic (hemoglobin (Hb) ≤10 g/dl) CKD patients not on dialysis. Epoetin alfa 10,000 U was administered subcutaneously once weekly for 16 weeks. Titration to 20,000 U once weekly at week 5 was permitted if patients had an increase in Hb < 1 g/dl. Safety and efficacy were assessed by changes in health-related quality of life (Linear Analog Scale Assessment (LASA) and Kidney Disease Questionnaire (KDQ)), changes in hematologic parameters and transfusion utilization, and incidence and severity of adverse events. Results: 1,338 patients were evaluable for efficacy. Mean Hb level increased from 9.1 g/dl at baseline to 11. 6 g/dl at study completion (last observed value after baseline) (p < 0.0001). Overall, 89.8{\%} of patients responded to once-weekly dosing, exhibiting an increase in Hb level of ≥ 1 g/dl from baseline. The percentage of patients that required transfusion decreased from 11.1{\%} (baseline) to 3.7{\%} (during the study) (p < 0.0001). All quality-of-life parameters improved significantly from baseline (p < 0.0001). Mean LASA scores for energy, activity and overall quality of life increased from baseline to study completion by 27.9 mm (70.5{\%}), 24.5 mm (57.0{\%}) and 22.6 mm (47.4{\%}), respectively. All 5 KDQ domains showed statistically significant improvements (p < 0.0001). Hb change was a strong predictor for all 5 KDQ domains and the overall score (p < 0.0001). Treatment with once-weekly epoetin alfa was well tolerated, similar to that reported with three times-weekly dosing. Conclusion: Once-weekly epoetin alfa therapy is safe and effective for treating anemia in patients with CKD not on dialysis, and is associated with significant improvements in functional status and quality of life.",
keywords = "Anemia, Chronic kidney disease, Epoetin alfa, Hemoglobin, Once weekly dosing, Quality of life",
author = "R. Provenzano and L. Gracia-Mayol and P. Suchinda and {Von Hartitzsch}, B. and Woollen, {S. B.} and R. Zabaneh and Fink, {J. C.} and Boorgu, {N. R.} and Habach, {G. A.} and W. McGuffin and Shaver, {M. J.} and D. Chan and A. Trivedi and J. Ahdoot and M. Blumenkrantz and Al-Mufti, {H. L.} and C. Covey and A. Dauer and N. DiDomenico and Elder, {J. G.} and Fadda, {G. Z.} and E. Feinstein and Fernandez, {R. J.} and J. Glick and J. Golden and Healy, {M. D.} and Kleinman, {K. S.} and Lee, {P. H.} and Maciejewski, {A. R.} and L. Mehandru and Naughton, {J. L.} and R. Oliver and T. Nguyen and Patek, {R. V.} and A. Rahban and D. Ricker and D. Roh and R. Sankaram and L. Schoenfeld and A. Semerjian and M. Shapiro and Sun, {C. H.} and S. Sunderrajan and Waldman, {R. P.} and Klein, {M. H.} and Kuruvila, {K. C.} and H. Lifland and F. Walsh and V. Habwe and Sethi, {Kapil Dev} and Zonozi, {M. S.} and Kasama, {R. K.} and J. Barrero and D. Butcher and V. Bommineni and D. Celaya and J. Cohen and J. DiMare and Galvez, {O. G.} and L. Garcia-Mayol and R. Geronemus and Glasser, {C. M.} and Hoffman, {D. S.} and P. Kar and Littlefield, {J. M.} and J. Mahmood and Moros, {J. G.} and J. Narayan and J. Navarro and Pellegrini, {E. L.} and E. Perez and P. Reddy and A. Sallman and M. Sobel and Spies, {C. P.} and B. Erb and Fariyike, {B. T.} and Feinsmith, {L. S.} and J. Hertel and Hicks, {M. W.} and Kassem, {M. M.} and M. Katz and G. Knowlton and R. Loutoby and C. Martinez and Murphy, {S. T.} and Orig, {M. J.C.} and Pimentel, {J. L.} and P. Pintavorn and R. Shay and A. Vainer and Wilkowski, {M. J.} and D. Williamson and Woollen, {S. B.} and S. DaHal and S. Hallberg and V. Kantamneni and M. Matson and D. Batlle",
year = "2004",
month = "1",
day = "1",
doi = "10.5414/CNP61392",
language = "English (US)",
volume = "61",
pages = "392--405",
journal = "Clinical Nephrology",
issn = "0301-0430",
publisher = "Dustri-Verlag Dr. Karl Feistle",
number = "6",

}

TY - JOUR

T1 - Once-weekly epoetin alfa for treating the anemia of chronic kidney disease

AU - Provenzano, R.

AU - Gracia-Mayol, L.

AU - Suchinda, P.

AU - Von Hartitzsch, B.

AU - Woollen, S. B.

AU - Zabaneh, R.

AU - Fink, J. C.

AU - Boorgu, N. R.

AU - Habach, G. A.

AU - McGuffin, W.

AU - Shaver, M. J.

AU - Chan, D.

AU - Trivedi, A.

AU - Ahdoot, J.

AU - Blumenkrantz, M.

AU - Al-Mufti, H. L.

AU - Covey, C.

AU - Dauer, A.

AU - DiDomenico, N.

AU - Elder, J. G.

AU - Fadda, G. Z.

AU - Feinstein, E.

AU - Fernandez, R. J.

AU - Glick, J.

AU - Golden, J.

AU - Healy, M. D.

AU - Kleinman, K. S.

AU - Lee, P. H.

AU - Maciejewski, A. R.

AU - Mehandru, L.

AU - Naughton, J. L.

AU - Oliver, R.

AU - Nguyen, T.

AU - Patek, R. V.

AU - Rahban, A.

AU - Ricker, D.

AU - Roh, D.

AU - Sankaram, R.

AU - Schoenfeld, L.

AU - Semerjian, A.

AU - Shapiro, M.

AU - Sun, C. H.

AU - Sunderrajan, S.

AU - Waldman, R. P.

AU - Klein, M. H.

AU - Kuruvila, K. C.

AU - Lifland, H.

AU - Walsh, F.

AU - Habwe, V.

AU - Sethi, Kapil Dev

AU - Zonozi, M. S.

AU - Kasama, R. K.

AU - Barrero, J.

AU - Butcher, D.

AU - Bommineni, V.

AU - Celaya, D.

AU - Cohen, J.

AU - DiMare, J.

AU - Galvez, O. G.

AU - Garcia-Mayol, L.

AU - Geronemus, R.

AU - Glasser, C. M.

AU - Hoffman, D. S.

AU - Kar, P.

AU - Littlefield, J. M.

AU - Mahmood, J.

AU - Moros, J. G.

AU - Narayan, J.

AU - Navarro, J.

AU - Pellegrini, E. L.

AU - Perez, E.

AU - Reddy, P.

AU - Sallman, A.

AU - Sobel, M.

AU - Spies, C. P.

AU - Erb, B.

AU - Fariyike, B. T.

AU - Feinsmith, L. S.

AU - Hertel, J.

AU - Hicks, M. W.

AU - Kassem, M. M.

AU - Katz, M.

AU - Knowlton, G.

AU - Loutoby, R.

AU - Martinez, C.

AU - Murphy, S. T.

AU - Orig, M. J.C.

AU - Pimentel, J. L.

AU - Pintavorn, P.

AU - Shay, R.

AU - Vainer, A.

AU - Wilkowski, M. J.

AU - Williamson, D.

AU - Woollen, S. B.

AU - DaHal, S.

AU - Hallberg, S.

AU - Kantamneni, V.

AU - Matson, M.

AU - Batlle, D.

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Background and aim: Anemia occurs in approximately 47% of patients with chronic kidney disease (CKD) not on dialysis. Recombinant human erythropoietin (r-HuEPO, epoetin alfa) has been proven safe and effective for anemia treatment in patients with CKD using a three times-weekly regimen. The current study was conducted to evaluate the clinical safety and efficacy of a less frequent dosing regimen (once weekly) in this population. Methods: This prospective, multicenter, open-label, non-randomized study enrolled 1,557 adult anemic (hemoglobin (Hb) ≤10 g/dl) CKD patients not on dialysis. Epoetin alfa 10,000 U was administered subcutaneously once weekly for 16 weeks. Titration to 20,000 U once weekly at week 5 was permitted if patients had an increase in Hb < 1 g/dl. Safety and efficacy were assessed by changes in health-related quality of life (Linear Analog Scale Assessment (LASA) and Kidney Disease Questionnaire (KDQ)), changes in hematologic parameters and transfusion utilization, and incidence and severity of adverse events. Results: 1,338 patients were evaluable for efficacy. Mean Hb level increased from 9.1 g/dl at baseline to 11. 6 g/dl at study completion (last observed value after baseline) (p < 0.0001). Overall, 89.8% of patients responded to once-weekly dosing, exhibiting an increase in Hb level of ≥ 1 g/dl from baseline. The percentage of patients that required transfusion decreased from 11.1% (baseline) to 3.7% (during the study) (p < 0.0001). All quality-of-life parameters improved significantly from baseline (p < 0.0001). Mean LASA scores for energy, activity and overall quality of life increased from baseline to study completion by 27.9 mm (70.5%), 24.5 mm (57.0%) and 22.6 mm (47.4%), respectively. All 5 KDQ domains showed statistically significant improvements (p < 0.0001). Hb change was a strong predictor for all 5 KDQ domains and the overall score (p < 0.0001). Treatment with once-weekly epoetin alfa was well tolerated, similar to that reported with three times-weekly dosing. Conclusion: Once-weekly epoetin alfa therapy is safe and effective for treating anemia in patients with CKD not on dialysis, and is associated with significant improvements in functional status and quality of life.

AB - Background and aim: Anemia occurs in approximately 47% of patients with chronic kidney disease (CKD) not on dialysis. Recombinant human erythropoietin (r-HuEPO, epoetin alfa) has been proven safe and effective for anemia treatment in patients with CKD using a three times-weekly regimen. The current study was conducted to evaluate the clinical safety and efficacy of a less frequent dosing regimen (once weekly) in this population. Methods: This prospective, multicenter, open-label, non-randomized study enrolled 1,557 adult anemic (hemoglobin (Hb) ≤10 g/dl) CKD patients not on dialysis. Epoetin alfa 10,000 U was administered subcutaneously once weekly for 16 weeks. Titration to 20,000 U once weekly at week 5 was permitted if patients had an increase in Hb < 1 g/dl. Safety and efficacy were assessed by changes in health-related quality of life (Linear Analog Scale Assessment (LASA) and Kidney Disease Questionnaire (KDQ)), changes in hematologic parameters and transfusion utilization, and incidence and severity of adverse events. Results: 1,338 patients were evaluable for efficacy. Mean Hb level increased from 9.1 g/dl at baseline to 11. 6 g/dl at study completion (last observed value after baseline) (p < 0.0001). Overall, 89.8% of patients responded to once-weekly dosing, exhibiting an increase in Hb level of ≥ 1 g/dl from baseline. The percentage of patients that required transfusion decreased from 11.1% (baseline) to 3.7% (during the study) (p < 0.0001). All quality-of-life parameters improved significantly from baseline (p < 0.0001). Mean LASA scores for energy, activity and overall quality of life increased from baseline to study completion by 27.9 mm (70.5%), 24.5 mm (57.0%) and 22.6 mm (47.4%), respectively. All 5 KDQ domains showed statistically significant improvements (p < 0.0001). Hb change was a strong predictor for all 5 KDQ domains and the overall score (p < 0.0001). Treatment with once-weekly epoetin alfa was well tolerated, similar to that reported with three times-weekly dosing. Conclusion: Once-weekly epoetin alfa therapy is safe and effective for treating anemia in patients with CKD not on dialysis, and is associated with significant improvements in functional status and quality of life.

KW - Anemia

KW - Chronic kidney disease

KW - Epoetin alfa

KW - Hemoglobin

KW - Once weekly dosing

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=2942744923&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942744923&partnerID=8YFLogxK

U2 - 10.5414/CNP61392

DO - 10.5414/CNP61392

M3 - Article

VL - 61

SP - 392

EP - 405

JO - Clinical Nephrology

JF - Clinical Nephrology

SN - 0301-0430

IS - 6

ER -